Shingles vaccine

Bibliography

• Arvin A. Varicella-zoster virus. Clin Microbiol Rev 1996;9:361-81
   PubMed Web of Science ®Google Scholar
• Harpaz R, Ortega-Shanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008;57:1-30
   PubMedGoogle Scholar
• Kimberlin DW, Whitley RJ. Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med 2007;356:1338-43
   PubMed Web of Science ®Google Scholar
• Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes zoster. Arch Intern Med 1995;155:1605-9
   PubMed Web of Science ®Google Scholar
• Ragozzino MW, Melton LJ III, Kurland LT, Population-based study of herpes zoster and its sequelae. Medicine 1982;61:310-6
   PubMed Web of Science ®Google Scholar
• Gnann JW Jr, Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med 2002;347:340-6
   PubMed Web of Science ®Google Scholar
• Yawn BP, Saddier S, Wollan P, A population-based study of the incidence and complications of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007;82:1341-9
   PubMed Web of Science ®Google Scholar
• Arvin A. Aging, immunity, and the varicella-zoster virus. N Engl J Med 2005;352:2266-7
   PubMed Web of Science ®Google Scholar
• Arvin A. Cell-mediated immunity to varicella-zoster virus. J Infect Dis 1992;166:S35-41
   PubMed Web of Science ®Google Scholar
• Kimberlin DW, Whitley RJ. Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med 2007;356:1338-43
   PubMed Web of Science ®Google Scholar
• Hope-Simpson RE. The nature of herpes zoster: a long term study and a new hypothesis. Proc R Soc Med 1965;58:9-21
   PubMedGoogle Scholar
• Kost RG, Straus SE. Postherpetic neuralgia – pathogenesis, treatment, and prevention. N Engl J Med 1996;335:32-42
   PubMed Web of Science ®Google Scholar
• Berger R, Florent G, Just M. Decrease of the lymphoproliferative response to varicella-zoster virus antigen in the aged. Infect Immun 1981;32:24-7
   PubMed Web of Science ®Google Scholar
• Burke BL, Steele RW, Beard OW, Immune responses to varicella-zoster in the aged. Arch Intern Med 1982;142:291-3
   PubMed Web of Science ®Google Scholar
• Dolin R, Reichman RC, Mazur MH, Whitley RJ. NIH conference: herpes zoster-varicella infections in immunosuppressed patients. Ann Intern Med 1978;89:375-88
   PubMed Web of Science ®Google Scholar
• Galil K, Choo PW, Donahue JG, Platt R. The sequelae of herpes zoster. Arch Intern Med 1997;157:1209-13
   PubMed Web of Science ®Google Scholar
• Wilson A, Sharp M, Koropchak CM, Subclinical varicella zoster viral antigens after bone marrow transplantation. J Infect Dis 1992;165:119-26
   PubMed Web of Science ®Google Scholar
• Buchbinder SP, Katz MH, Hessol NA, Herpes zoster and human immunodeficiency virus infection. J Infect Dis 1992;166:1153-6
   PubMed Web of Science ®Google Scholar
• Weinberg JM. Herpes zoster: epidemiology, natural history, and common complications. J Am Acad Dermatol 2007;57:S130-5
   PubMed Web of Science ®Google Scholar
• Hicks LD, Cook-Norris RH, Mendoza N, Family history as a risk factor for herpes zoster: a case–control study. Arch Dermatol 2008;144:603-8
   PubMed Web of Science ®Google Scholar
• Arani RB, Soong SJ, Weiss HL, Phase specific analysis of herpes zoster associated pain data: a new statistical approach. Stat Med 2001;20:2429-39
   PubMed Web of Science ®Google Scholar
• Desmond RA, Weiss HL, Arani RB, Clinical application for change-point analysis of herpes zoster pain. J Pain Symptom Manage 2002;23:510-6
   PubMed Web of Science ®Google Scholar
• Jung BF, Johnson RW, Griffin DRJ, Dworkin RH. Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology 2004;62:1545-51
   PubMed Web of Science ®Google Scholar
• Gilden DH, Kleinschmidt-Demasters BK, Laguardia JJ, Neurologic complications of the reactivation of varicella-zoster virus. N Engl J Med 2000;342:635-45
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Johnson RW, Breuer J, Recommendations for the management of herpes zoster. Clin Infect Dis 2007;44(Suppl 1):S1-26
   PubMedGoogle Scholar
• Dworkin RH, Schmader KE. Treatment and prevention of postherpetic neuralgia. Clin Infect Dis 2003;36:877-82
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Portenoy RK. Proposed classification of herpes zoster pain. Lancet 1994;343:1648
   PubMed Web of Science ®Google Scholar
• Katz J, Cooper EM, Walther RR, Acute pain in herpes zoster and its impact on health related quality of life. Clin Infect Dis 2004;39:342-8
   PubMed Web of Science ®Google Scholar
• Kim DH, Kumar D, Messner HA, Clinical efficacy of prophylactic strategy of long-term low-dose acyclovir for varicella-zoster virus infection after allogeneic peripheral blood stem cell transplantation. Clin Transplant 2008;22:770-9
   PubMed Web of Science ®Google Scholar
• Sullivan KM, Dykewicz CA, Longworth DL, Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and America Society for Blood and Marrow Transplantation Practice Guidelines and beyond. Hematology Am Soc Hematol Educ Program 2001:392-401
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention; Infectious Diseases Society of America; American Society of Blood and Marrow Transplantation. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 2000;6:659-713, 715,717-727; quiz 729
   PubMed Web of Science ®Google Scholar
• Kim DH, Messner H, Minden M, Factors influencing varicella-zoster virus infection after allogeneic peripheral blood stem cell transplantation: low-dose acyclovir prophylaxis and pre-transplant diagnosis of lymphoproliferative disorders. Transplant Infect Dis 2008;10:90-8
   PubMed Web of Science ®Google Scholar
• Takahashi M, Asano Y, Kamiya H, Development of varicella vaccine. J Infect Dis 2008;197(Suppl 2):S41-S44
   PubMedGoogle Scholar
• Takahashi M, Otsuka T, Okuno Y, Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 1974;2:1288-90
   PubMed Web of Science ®Google Scholar
• Asano Y, Nagai T, Miyata T, Long-term protective immunity of recipients of the Oka strain of live varicella vaccine. Pediatrics 1985;75:667-71
   PubMed Web of Science ®Google Scholar
• Weibel RE, Neff BJ, Kuter BJ, Live attenuated varicella virus vaccine: efficacy trial in healthy children. N Engl J Med 1984;310:1409-15
   PubMed Web of Science ®Google Scholar
• Gershon AA, Steinberg SP, Larussa P, Immunization of healthy adults with live-attenuated varicella vaccine. J Infect Dis 1988;158:132-7
   PubMed Web of Science ®Google Scholar
• Levin MJ, Smith JG, Kaufhold RM, Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis 2003;188:1336-44
   PubMed Web of Science ®Google Scholar
• Takahashi M, Ikatani T, Sasada K, Immunization of the elderly and patients with collagen vascular diseases with live varicella vaccine and use of varicella skin antigen. J Infect Dis 1992;166:S58-62
   PubMed Web of Science ®Google Scholar
• Levin MJ, Barber D, Goldblatt E, Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: duration of booster effect. J Infect Dis 1998;178:S109-12
   PubMed Web of Science ®Google Scholar
• Trannoy E, Berger R, Hollander G, Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial. Vaccine 2000;18:1700-6
   PubMed Web of Science ®Google Scholar
• Oxman MN, Levin MJ, Johnson GR, A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352:2271-84
   PubMed Web of Science ®Google Scholar
• Oxman MN, Levin MJ. Vaccination against herpes zoster and postherpetic Neuralgia. J Infect Dis 2008;197(Suppl 2):S228-S236
   PubMedGoogle Scholar
• Merck. ZOSTAVAX® Package Insert. 2009. Available from: http://www.merck.com/product/usa/pi_circulars/z/ zostavax/zostavax_pi.pdf. [Last accessed 18 January 2010]
   Google Scholar
• Oxman MN. Immunization to reduce the frequency and severity of herpes zoster and its complications. Neurology 1995;45(Suppl 8):S41-S46
   PubMedGoogle Scholar
• Schmader K, Saddier P, Johnson G, The effect of a zoster vaccine on interference of herpes zoster with activities of daily living (ADL) [abstract 859]. 44th Annual Meeting of IDSA, 12-15 October 2006, Toronto
   Google Scholar
• Rohan P. FDA Clinical Briefing Document for Merck & Co., Inc. Zoster vaccine live (Oka/Merck)Zostavax™. Washington, DC:Food & Drug Administration, Vaccines & Related Biological Products Advisory Committee, 2005. Available from: http://www.fda.gov/OHRMS/DOCKETS/ac/05/briefing/5-4198B2_1.pdf. [Last accessed 18 January 2010]
   Google Scholar
• Kilgore PE, Kruszon-Moran D, Seward JF, Varicella in Americans from NHANES III: implications for control through routine immunization. J Med Virol 2003;70 (Suppl 1):S111-S118
   PubMedGoogle Scholar
• CDC Vaccine Price List: Adult Vaccine Price List. 2009. Atlanta, GA: Centers for Disease Control and Prevention, 2009. Available from: http://www.cdc.gov/vaccines/programs/vfc/cdc-vac-price-list.htm#adult. [Last accessed 18 January 2010]
   Google Scholar